Form 4: Maravai LifeSciences CFO Kevin Herde Reports Acquisition of Class A Common Stock

Kevin Herde, CFO of Maravai LifeSciences Holdings, Inc., reports the acquisition of 394,478 shares of Class A Common Stock through restricted stock units.

Summary

• On March 17, 2025, Kevin Herde, the Chief Financial Officer of Maravai LifeSciences Holdings, Inc., acquired 394,478 shares of Class A Common Stock.
• This acquisition was through the awarding of restricted stock units (RSUs) under the company's 2020 Omnibus Incentive Plan.
• Following the transaction, Herde directly owns 673,760 shares of Class A Common Stock.
• The RSUs vest in three equal installments on March 15, 2026, March 15, 2027, and March 15, 2028, contingent upon continued employment with Maravai LifeSciences.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The acquisition of shares by the CFO suggests confidence in the company, but it's a routine transaction.

Positives

• The acquisition of shares by a key executive can be seen as a positive sign, indicating confidence in the company's future performance.
• The vesting schedule of the RSUs incentivizes the CFO to remain with the company for the long term.

Future Outlook

The vesting of the RSUs is contingent upon the Reporting Person's continued employment with the Issuer.

Industry Context

This filing is a routine disclosure related to executive compensation and stock ownership, common in publicly traded companies. It provides transparency to investors regarding the holdings of key personnel.

Stakeholder Impact

• The increased ownership stake of a key executive could positively influence investor sentiment.

Key Dates

Keywords

Maravai LifeSciences, MRVI, Kevin Herde, CFO, Class A Common Stock, Restricted Stock Units, RSUs, Beneficial Ownership, SEC Form 4